XRX-001

XRX-001 is an inactivated, whole-virion yellow fever vaccine derived from the 17D strain. It was developed as a safer, non-replicating alternative to the standard live-attenuated 17D vaccine (such as YF-VAX or Stamaril), which is associated with rare but severe adverse events like vaccine-associated viscerotropic and neurotropic disease. XRX-001 is produced in Vero cell cultures using single-use biomanufacturing technology, inactivated with $\beta$-propiolactone, and adsorbed to an aluminum hydroxide (alum) adjuvant. This cell-culture-based approach also eliminates the risk of allergic reactions in individuals with egg hypersensitivity. Originally developed by Xcellerex, the asset was acquired by GE Healthcare in 2012 and subsequently by PnuVax in 2016. A Phase 1 clinical trial (NCT00995865) demonstrated that the vaccine was well-tolerated and highly immunogenic, inducing neutralizing antibodies in up to 100% of healthy adult subjects.

Other names

inactivated yellow fever vaccineXRX-001 inactivated yellow fever vaccineXRX001 inactivated yellow fever vaccineXRX 001 inactivated yellow fever vaccineXRX-001 yellow fever 17D, inactivated vaccine, alum adsorbed